JPMorgan CEO gives more details about the healthcare venture with Amazon, Berkshire Hathaway; a White House report on insurers comes under scrutiny; a database tracks pharmaceutical donations to patient groups.
JPMorgan CEO Jamie Dimon gave more details about the partnership between Amazon, Berkshire Hathaway, and his institution in his annual letter to the bank’s shareholders, Bloomberg reported. The letter suggests that the timeline will be long and the venture would start small, with priorities focused on aligning incentives among doctors, insurers, and patients; reducing fraud and waste; giving employees more access to telemedicine and better wellness programs; and figuring out why so much money is spent on end-of-life care. He also said the partnership will use big data and virtual technology.
Last month, the White House released a report from its Council of Economic Advisers (CEA) claiming that health insurers were doing well. But the report does not stand up to fact-based objective economic analysis, which is what the CEA is supposed to do even as it supports a president’s policies, The Washington Post reported. In particular, the Post cited the creation of a stock index of insurers that are no longer in the individual marketplace as one piece of the flawed report.
Kaiser Health News created a database to track pharmaceutical company donations to patient advocacy groups and found that companies gave at least $116 million in a single year, more than their lobbying expenditures. The database logged 12,000 donations in 2015, the most recent full year in which documents required by the IRS were available. Companies do not have to report these payments, and experts said the ties to patients groups could be troubling if the groups then do not act in the best interests of the patients they serve. For instance, some patient groups have been silent on or slow to complain about rising drug costs.
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Homelessness Compounds Hospital Stay Challenges: Study Reveals Prolonged Discharge Struggles
March 28th 2024In this investigation, outcomes of interest were morbidity rate and length of hospital stay or a traumatic injury among a homeless population, and whether age and/or injury severity had an influence on that relationship—with implications for improving the discharge process for these patients.
Read More
FDA Approves Vadadustat for Anemia in Patients With CKD Undergoing Dialysis
March 28th 2024The FDA approved vadadustat (Vafseo), an oral medication, to treat anemia in adult patients with chronic kidney disease (CKD) on dialysis for at least 3 months. This fills a need for a new treatment option as anemia is common in these patients and can significantly impact their quality of life.
Read More